文献速递造血干细胞移植与细胞治疗淋巴瘤浆细胞疾病

应用EHA/EBMT的ICAHT分级评估CAR-T后细胞减少:比较发生率及其与感染和死亡率的关系

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
PubMed 文献 · Blood Adv · 2024-01-01

这项多中心观察性研究将新型EHA/EBMT的ICAHT分级应用于549例接受BCMA或CD19靶向CAR-T治疗的难治性B细胞恶性肿瘤患者,发现ICAHT分级与严重中性粒细胞减少累积持续时间强相关(r=0.92,P<.0001),严重ICAHT与更高的严重感染率、非复发死亡率和更差的生存相关,且预测严重感染的能力优于CTCAE分级(c-index 0.73 vs 0.55,P<.0001 vs 无统计学意义)。

要点

  • ICAHT分级与严重中性粒细胞减少累积持续时间强相关(r=0.92,P<.0001)。
  • 严重ICAHT与严重感染率49% vs 13%(P<.0001)及非复发死亡率14% vs 4%(P<.0001)升高相关。
  • ICAHT分级预测严重感染的c-index为0.73,优于CTCAE的0.55(P<.0001 vs 无统计学意义)。

核心结论

  • 这些数据突显了新型ICAHT分级系统的临床相关性,并支持在评估CAR-T疗法的临床试验中报告ICAHT严重程度。

研究设计与样本

  • 多中心观察性研究,纳入549例接受BCMA或CD19靶向CAR-T治疗难治性B细胞恶性肿瘤的患者,其中多发性骨髓瘤(MM)112例、大B细胞淋巴瘤(LBCL)334例、套细胞淋巴瘤(MCL)103例。

主要发现

  • ICAHT分级与严重中性粒细胞减少累积持续时间强相关(r=0.92,P<.0001)。
  • ICAHT分级与多系血细胞减少以及血小板和红细胞输注的使用相关。
  • 严重ICAHT发生率在MCL患者为28%,LBCL患者为23%,MM患者为15%。
  • 严重ICAHT与更高的严重感染率相关(49% vs 13%,P<.0001),与非复发死亡率升高相关(14% vs 4%,P<.0001),与更差的生存结局相关(1年无进展生存率35% vs 51%,1年总生存率52% vs 73%,均P<.0001)。
  • ICAHT分级预测严重感染的能力优于CTCAE分级(c-index 0.73 vs 0.55,P<.0001 vs 无统计学意义)。

关键数值与推荐

  • ICAHT分级与严重中性粒细胞减少累积持续时间的相关系数r=0.92(P<.0001)。
  • 严重ICAHT发生率:MCL 28% vs LBCL 23% vs MM 15%。
  • 严重ICAHT组 vs 非严重ICAHT组的严重感染率:49% vs 13%(P<.0001)。
  • 严重ICAHT组 vs 非严重ICAHT组的非复发死亡率:14% vs 4%(P<.0001)。
  • 严重ICAHT组 vs 非严重ICAHT组的1年无进展生存率:35% vs 51%,1年总生存率:52% vs 73%(均P<.0001)。

临床怎么用

  • 原文结论支持在评估CAR-T疗法的临床试验中报告ICAHT严重程度,未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can predispose for severe infectious complications. Current grading systems, such as the Common Terminology Criteria for Adverse Events (CTCAE), neither reflect the unique quality of post-CAR-T neutrophil recovery, nor do they reflect the inherent risk of infections due to protracted neutropenia. For this reason, a novel EHA/EBMT consensus grading was recently developed for Immune Effector Cell-Associated HematoToxicity (ICAHT). In this multicenter, observational study, we applied the grading system to a large real-world cohort of 549 patients treated with BCMA- or CD19-directed CAR-T for refractory B-cell malignancies (112 multiple myeloma [MM], 334 large B-cell lymphoma [LBCL], 103 mantle cell lymphoma [MCL]) and examined the clinical sequelae of severe (≥3°) ICAHT. The ICAHT grading was strongly associated with the cumulative duration of severe neutropenia (r = 0.92, P < .0001), the presence of multilineage cytopenias, and the use of platelet and red blood cell transfusions. We noted an increased rate of severe ICAHT in patients with MCL vs those with LBCL and MM (28% vs 23% vs 15%). Severe ICAHT was associated with a higher rate of severe infections (49% vs 13%, P < .0001), increased nonrelapse mortality (14% vs 4%, P < .0001), and inferior survival outcomes (1-year progression-free survival: 35% vs 51%, 1-year overall survival: 52% vs 73%, both P < .0001). Importantly, the ICAHT grading demonstrated superior capacity to predict severe infections compared with the CTCAE grading (c-index 0.73 vs 0.55, P < .0001 vs nonsignificant). Taken together, these data highlight the clinical relevance of the novel grading system and support the reporting of ICAHT severity in clinical trials evaluating CAR-T therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rejeski K, Wang Y, Hansen DK, et al. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024. PMID: 38181508. doi:10.1182/bloodadvances.2023011767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。